Liver disease biotech Lumena Pharmaceuticals files for a $75 million IPO

By
A A A

Lumena Pharmaceuticals, a clinical-stage biotech developing candidates for rare liver diseases, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. The San Diego, CA-based company, which was founded in 2011, plans to list on the NASDAQ under the symbol LIVR. Lumena Pharmaceuticals initially filed confidentially on February 28, 2014. Citi, Cowen & Company and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

The Pumpkin Carvers
The Pumpkin Carvers                 

Stocks

Referenced

Most Active by Volume

88,066,694
  • $97.19 ▲ 2.61%
58,241,731
  • $71.29 ▲ 2.92%
51,058,864
  • $44.87 ▲ 0.09%
48,927,829
  • $28.75 ▲ 0.81%
46,551,917
    $15.52 unch
40,249,498
  • $3.46 ▼ 0.57%
38,633,031
  • $22.43 ▼ 9.63%
38,240,825
  • $34.71 ▲ 3.30%
As of 7/23/2014, 04:04 PM